Oral Tirzepatide in 2026: Who Actually Offers It and What It Costs
Oral tirzepatide is harder to find than oral semaglutide. While a dozen-plus providers now offer compounded oral sema, only four to five currently offer compounded oral tirzepatide — and there's no FDA-approved oral tirzepatide yet (Lilly's Foundayo is a different molecule, orforglipron, not tirzepatide).
If you specifically want the dual GLP-1/GIP mechanism of tirzepatide in an oral format, here's where you can get it and what you'll pay.
Why Oral Tirzepatide Is Rare
Tirzepatide is a larger, more complex molecule than semaglutide, which makes oral delivery more challenging from a compounding standpoint. The absorption questions that apply to all compounded oral GLP-1s are even more pronounced with tirzepatide. Several providers who offer oral sema have explicitly chosen not to offer oral tirz, citing insufficient data on oral bioavailability.
Every Oral Tirzepatide Provider
| Provider | Format | Monthly Price |
|---|---|---|
| MadeMed | Sublingual | $229 |
| Wellorithm | Compounded tablets | $249 |
| Sprout Health | Dissolvable tablet | $249–$299 |
| SkinnyRx | Buccal tablet | $299 |
| Synergy Rx | ODT | $399 |
Provider Reviews
MadeMed offers the cheapest oral tirzepatide at $229/month via sublingual delivery. They also carry oral semaglutide starting at $99/month, making them one of the few providers where you can try either molecule in oral form.
SkinnyRx uses a buccal tablet format for oral tirzepatide at $299/month. Their $500 CPA and established reputation make them a reliable option, and they also offer oral semaglutide at $199/month if you want to compare both.
Should You Choose Oral Tirzepatide?
Tirzepatide's dual GLP-1/GIP mechanism has shown stronger weight loss results in clinical trials compared to semaglutide alone. The SURMOUNT trials demonstrated up to 22.5% body weight reduction with injectable tirzepatide. If you've plateaued on semaglutide or want the dual-agonist approach, tirzepatide is the logical step up.
The oral delivery question is where it gets complicated. The compounded oral versions lack the clinical data that injectable tirzepatide has, and the absorption profiles of sublingual/buccal/dissolvable formats haven't been validated in large trials. You're essentially betting on the medication reaching therapeutic levels through a non-standard delivery route.
For patients who can't tolerate injections, compounded oral tirzepatide is a reasonable option to discuss with your prescribing provider. For everyone else, injectable tirzepatide remains the better-studied choice.
The Foundayo Clarification
A common confusion: Foundayo (approved April 2026) is not oral tirzepatide. Foundayo's active ingredient is orforglipron — a different GLP-1 receptor agonist that happens to also be a daily oral pill. It works on GLP-1 receptors only (not dual GLP-1/GIP like tirzepatide). Lilly has not yet brought tirzepatide itself to market in oral form, though oral tirzepatide formulations are in their pipeline.